+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

COVID-19 Vaccine

  • ID: 5146593
  • Report
  • September 2020
  • Region: Global
  • 1 Pages
  • RM Landing Pages
1 of 1
Johnson & Johnson Enter Final Stage Vaccine Trial with 60,000 Volunteers

Johnson &amp; Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile. Johnson &amp; Johnson's vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.<br /><br />The company has committed to manufacturing a billion doses of the vaccine on a not for profit basis if proven effective. In contrast to other vaccine candidates that require at least two doses, J &amp; J's candidate requires just one dose. It also does not require freezing and can remain viable in its liquid form for several months. If the phase 3 trial is successful, both factors could have significant practical advantages for mass vaccination programs. <br /><br />We have included a selection of our most popular market research on COVID-19 vaccines below.
Note: Product cover images may vary from those shown
Adroll
adroll